Cencora, Inc. (NYSE:COR) Shares Sold by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. decreased its holdings in Cencora, Inc. (NYSE:COR) by 0.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 101,332 shares of the company’s stock after selling 899 shares during the period. Asset Management One Co. Ltd. owned approximately 0.05% of Cencora worth $22,808,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of COR. New Millennium Group LLC acquired a new stake in shares of Cencora in the second quarter valued at approximately $26,000. TCTC Holdings LLC acquired a new stake in shares of Cencora in the 1st quarter worth $29,000. TFO Wealth Partners LLC purchased a new position in shares of Cencora during the 1st quarter worth $30,000. LRI Investments LLC acquired a new position in shares of Cencora during the 1st quarter valued at about $31,000. Finally, MFA Wealth Advisors LLC purchased a new stake in shares of Cencora in the second quarter valued at about $30,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Evercore ISI reduced their target price on shares of Cencora from $270.00 to $250.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Wells Fargo & Company upped their price objective on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Robert W. Baird reduced their target price on Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research report on Friday, September 6th. Finally, Leerink Partners lowered their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a report on Monday, October 7th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $259.44.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the sale, the chairman now directly owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 15.80% of the company’s stock.

Cencora Stock Performance

NYSE COR opened at $233.93 on Wednesday. The company has a market cap of $46.10 billion, a P/E ratio of 25.40, a P/E/G ratio of 1.49 and a beta of 0.44. Cencora, Inc. has a 1-year low of $191.11 and a 1-year high of $247.66. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The stock has a 50-day moving average of $231.39 and a two-hundred day moving average of $230.54.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.